Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. (SUPN) Stock Overview
Explore Supernus Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
1.9B
P/E Ratio
30.20
EPS (TTM)
$1.11
ROE
0.06%
SUPN Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Supernus Pharmaceuticals, Inc. (SUPN) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 57.30, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $34.94.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 30.20 and a market capitalization of 1.9B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.